Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2024(Status and Outlook)

Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2024(Status and Outlook)



Report Overview: Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia. The Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size was estimated at USD 5721.97 million in 2023 and is projected to reach USD 7366.34 million by 2029, exhibiting a CAGR of 4.30% during the forecast period. This report provides a deep insight into the global Glucagon-like peptide 1 (GLP-1)-based Therapies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market. In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Glucagon-like peptide 1 (GLP-1)-based Therapies market in any manner. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Key Company Novo Nordisk AstraZeneca Eli Lily GSK Sanofi Bristol-Myers Squibb Abbott Laboratories Market Segmentation (by Type) Exenatied Liraglutide Lixisenatide Albiglutide Dulaglutide Market Segmentation (by Application) Hospital Pharmacy Geographic Segmentation • North America (USA, Canada, Mexico) • Europe (Germany, UK, France, Russia, Italy, Rest of Europe) • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) • South America (Brazil, Argentina, Columbia, Rest of South America) • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA) Key Benefits of This Market Research: • Industry drivers, restraints, and opportunities covered in the study • Neutral perspective on the market performance • Recent industry trends and developments • Competitive landscape & strategies of key players • Potential & niche segments and regions exhibiting promising growth covered • Historical, current, and projected market size, in terms of value • In-depth analysis of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market • Overview of the regional outlook of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Key Reasons to Buy this Report: • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change • This enables you to anticipate market changes to remain ahead of your competitors • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly • Provision of market value (USD Billion) data for each segment and sub-segment • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis • Provides insight into the market through Value Chain • Market dynamics scenario, along with growth opportunities of the market in the years to come • 6-month post-sales analyst support Customization of the Report In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met. Note: this report may need to undergo a final check or review and this could take about 48 hours. Chapter Outline Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods. Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term. Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market. Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis. Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc. Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years. Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years. Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Landscape
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2019-2024)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2019-2024)
3.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites, Area Served, Product Type
3.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.6.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.6.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Glucagon-like peptide 1 (GLP-1)-based Therapies Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Market Share by Type (2019-2024)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2019-2024)
7 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2019-2024)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2019-2024)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segmentation by Region
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 North America
8.2.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Novo Nordisk
9.1.1 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.1.4 Novo Nordisk Business Overview
9.1.5 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.1.6 Novo Nordisk Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 Eli Lily
9.3.1 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.3.5 Eli Lily Business Overview
9.3.6 Eli Lily Recent Developments
9.4 GSK
9.4.1 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.4.4 GSK Business Overview
9.4.5 GSK Recent Developments
9.5 Sanofi
9.5.1 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.5.4 Sanofi Business Overview
9.5.5 Sanofi Recent Developments
9.6 Bristol-Myers Squibb
9.6.1 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.6.4 Bristol-Myers Squibb Business Overview
9.6.5 Bristol-Myers Squibb Recent Developments
9.7 Abbott Laboratories
9.7.1 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.7.4 Abbott Laboratories Business Overview
9.7.5 Abbott Laboratories Recent Developments
10 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
10.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
10.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
10.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2025-2030)
11.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) Forecast by Application
11.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings